Cost of revenues was US$16,402,500 versus US$12,741,748, equal to 28.00% ofRevenueversus 29.39%.Gross Profitwas US$42,179,020 versus US$30,611,487, or 72.00% of revenue versus 70.61%.
The company said it continued to prioritize PDS0301, its investigational tumor-targeted IL-12 immunocytokine, as its lead development program, with ongoingClinical Trialsat the National Cancer Institute.
The company said third-quarter 2026 research expenses primarily related to initiation of its Phase 2/3 clinical trial for SIL204, in which the first patient was dosed on September 30, 2026. General and administrative expenses were US$1,398 thousand, versus US$1,135 thousand, an increase of 27.3%, …
Net income was US$78 thousand, versus a net loss of US$37.1 million in the second quarter of 2026 andNet Incomeof US$4.6 million a year earlier. Adjusted EBITDA, a non-GAAP measure, was US$22.4 million, versus US$13.5 million in the second quarter and US$13.7 million a …
Gross profit was US$1,487 thousand, or 27.4% of revenue, versus US$2,707 thousand, or 43.7%. The company attributed the lower margin primarily to adverse foreignExchange Ratefluctuations, revenue sharing expense, higher freight costs and tariffs. For the nine months, revenue was US$15,974 thousand versus US$16,953 thousand, …
The company noted that period comparisons are affected by changes in its reporting entity: the reverseRecapitalizationclosed on February 24, 2026, and Blackbox.io was deconsolidated on May 5, 2026. For the nine months, net revenues were US$1,923 thousand versus US$626 thousand, and gross margin was …
By stream,Advertisingtechnology and services revenue was US$11,169 thousand, with none a year earlier. Streaming and digital revenue was US$9,692 thousand versus US$9,558 thousand, media services revenue was US$3,110 thousand with none a year earlier, podcast and other revenue was US$1,067 thousand versus US$946 thousand, …
General and administrative expenses were US$4,048,851 versus US$3,474,059. The company said salaries and benefits in total decreased by US$144,794, withBonusexpense down US$1,865,131 because of a large one-time bonus in 2025 tied to its direct listing, and base salaries up US$1,497,896 to US$1,665,023 because of …
Other revenue was US$234 thousand versus US$606 thousand. The company said the 2026 amount consists of royalties recognized by Cyprium on net sales of ZYCUBO, and the prior-year amount of revenue from theSupplyof Amzeeq to Cutia.
The company said CARDAMYST (etripamil) nasal spray for the management of PSVT in the United States became available through U.S. retail pharmacies on January 26, 2026, and its national sales force was deployed in mid-February 2026. It said the license revenue came from a …